DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Catalytic Wealth RIA LLC

Catalytic Wealth RIA LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,446 shares of the medical device company’s stock after selling 287 shares during the quarter. Catalytic Wealth RIA LLC’s holdings in DexCom were worth $277,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New Hampshire acquired a new stake in shares of DexCom during the first quarter worth about $1,508,000. Eagle Asset Management Inc. lifted its position in shares of DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after purchasing an additional 310,728 shares in the last quarter. Alberta Investment Management Corp lifted its position in shares of DexCom by 27.0% during the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock worth $40,123,000 after purchasing an additional 68,723 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of DexCom by 62.5% during the first quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock worth $49,520,000 after purchasing an additional 137,336 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM traded down $0.28 during mid-day trading on Friday, reaching $69.34. 4,614,225 shares of the company’s stock were exchanged, compared to its average volume of 3,777,717. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market capitalization of $27.58 billion, a PE ratio of 44.74, a price-to-earnings-growth ratio of 2.18 and a beta of 1.16. The business’s fifty day simple moving average is $90.92 and its 200-day simple moving average is $114.58. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period last year, the firm posted $0.34 earnings per share. On average, equities research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,483 shares of company stock worth $369,052. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent research reports. Redburn Atlantic initiated coverage on shares of DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Canaccord Genuity Group restated a “buy” rating and set a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Finally, Stifel Nicolaus upped their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.